XFOR vs. VCXB, CLLS, CRDF, VXRT, CGEN, CRDL, GNFT, ADVM, VIGL, and ELEV
Should you be buying X4 Pharmaceuticals stock or one of its competitors? The main competitors of X4 Pharmaceuticals include 10X Capital Venture Acquisition Corp. III (VCXB), Cellectis (CLLS), Cardiff Oncology (CRDF), Vaxart (VXRT), Compugen (CGEN), Cardiol Therapeutics (CRDL), Genfit (GNFT), Adverum Biotechnologies (ADVM), Vigil Neuroscience (VIGL), and Elevation Oncology (ELEV). These companies are all part of the "biological products, except diagnostic" industry.
10X Capital Venture Acquisition Corp. III (NYSE:VCXB) and X4 Pharmaceuticals (NASDAQ:XFOR) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, risk, community ranking, institutional ownership, earnings, analyst recommendations, valuation and dividends.
13.3% of 10X Capital Venture Acquisition Corp. III shares are held by institutional investors. Comparatively, 72.0% of X4 Pharmaceuticals shares are held by institutional investors. 71.5% of 10X Capital Venture Acquisition Corp. III shares are held by insiders. Comparatively, 1.1% of X4 Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
X4 Pharmaceuticals received 71 more outperform votes than 10X Capital Venture Acquisition Corp. III when rated by MarketBeat users.
X4 Pharmaceuticals has a consensus price target of $3.00, indicating a potential upside of 223.14%. Given 10X Capital Venture Acquisition Corp. III's higher probable upside, analysts plainly believe X4 Pharmaceuticals is more favorable than 10X Capital Venture Acquisition Corp. III.
In the previous week, X4 Pharmaceuticals had 9 more articles in the media than 10X Capital Venture Acquisition Corp. III. MarketBeat recorded 10 mentions for X4 Pharmaceuticals and 1 mentions for 10X Capital Venture Acquisition Corp. III. X4 Pharmaceuticals' average media sentiment score of 1.68 beat 10X Capital Venture Acquisition Corp. III's score of 0.10 indicating that 10X Capital Venture Acquisition Corp. III is being referred to more favorably in the media.
X4 Pharmaceuticals' return on equity of 0.00% beat 10X Capital Venture Acquisition Corp. III's return on equity.
10X Capital Venture Acquisition Corp. III has a beta of 0.07, indicating that its share price is 93% less volatile than the S&P 500. Comparatively, X4 Pharmaceuticals has a beta of 0.51, indicating that its share price is 49% less volatile than the S&P 500.
Summary
X4 Pharmaceuticals beats 10X Capital Venture Acquisition Corp. III on 6 of the 11 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding XFOR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
X4 Pharmaceuticals Competitors List
Related Companies and Tools
